Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 531

1.

Significant Decreases in both Total and Unbound Lopinavir and Amprenavir Exposures during Co-administration: ACTG Protocol A5143/A5147s Results.

Dumond JB, Rigdon J, Mollan K, Tierney C, Kashuba AD, Aweeka F, Collier AC.

J Acquir Immune Defic Syndr. 2015 Jul 30. [Epub ahead of print]

PMID:
26230332
2.

Treatment of Chronic HCV Genotype 1 Coinfection.

Boesecke C, Rockstroh JK.

Curr HIV/AIDS Rep. 2015 Jul 31. [Epub ahead of print]

PMID:
26228050
3.

Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.

Esposito I, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Benítez-Gutiérrez L, Peña JM, Soriano V.

Expert Opin Drug Saf. 2015 Jul 27:1-14. [Epub ahead of print]

PMID:
26212044
4.

Natural history and treatment of Hepatitis C/HIV coinfection: is it time to change paradigms?

Arends JE, Lieveld F, Boeijen LL, de Kanter CT, van Erpecum KJ, Salmon D, Hoepelman AI, Asselah T, Ustianowski A.

J Hepatol. 2015 Jul 14. pii: S0168-8278(15)00462-6. doi: 10.1016/j.jhep.2015.06.034. [Epub ahead of print] Review.

PMID:
26186987
5.

Liver transplantation for hepatitis C virus in the era of direct-acting antiviral agents.

Audrey C, Raffaele B.

Curr Opin HIV AIDS. 2015 Jul 17. [Epub ahead of print]

PMID:
26185921
6.

A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.

Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Müllhaupt B, Metzner KJ, Decosterd L, Böni J, Weber R, Fehr J; Swiss HIV Cohort Study.

PLoS One. 2015 Jul 15;10(7):e0133028. doi: 10.1371/journal.pone.0133028. eCollection 2015.

7.

Drug-Drug Interactions in Patients Co-infected With HCV and HIV--Reply.

Osinusi A, Townsend K, Kottilil S.

JAMA. 2015 Jul 14;314(2):186-7. doi: 10.1001/jama.2015.6621. No abstract available.

PMID:
26172900
8.

Drug-Drug Interactions in Patients Co-infected With HCV and HIV.

Nozaki Y, Yanase M, Masaki N.

JAMA. 2015 Jul 14;314(2):186. doi: 10.1001/jama.2015.6618. No abstract available.

PMID:
26172899
9.

Drug Interactions of Hepatitis C Direct-Acting Antivirals in the HIV-Infected Person.

El-Sherif O, Back D.

Curr HIV/AIDS Rep. 2015 Jul 11. [Epub ahead of print]

PMID:
26159742
10.

Emerging Challenges in Managing Hepatitis B in HIV Patients.

Soriano V, Labarga P, de Mendoza C, Peña JM, Fernández-Montero JV, Benítez L, Esposito I, Barreiro P.

Curr HIV/AIDS Rep. 2015 Jul 9. [Epub ahead of print]

PMID:
26156570
11.

A Special Touch: Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection.

Toussaint-Miller KA, Andres J.

Ann Pharmacother. 2015 Jul 2. pii: 1060028015592015. [Epub ahead of print] Review.

PMID:
26139639
12.

Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.

Bollen P, Reiss P, Schapiro J, Burger D.

Expert Opin Drug Saf. 2015 Jul 1:1-16. [Epub ahead of print]

PMID:
26134478
13.

Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.

Ford N, Wiktor S, Kaplan K, Andrieux-Meyer I, Hill A, Radhakrishnan P, Londeix P, Forette C, Momenghalibaf A, Verster A, Swan T.

Int J Drug Policy. 2015 May 18. pii: S0955-3959(15)00137-1. doi: 10.1016/j.drugpo.2015.05.004. [Epub ahead of print]

PMID:
26074094
14.

Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.

Fazel Y, Lam B, Golabi P, Younossi Z.

Expert Opin Drug Saf. 2015 Aug;14(8):1317-26. doi: 10.1517/14740338.2015.1053868. Epub 2015 Jun 4.

PMID:
26043900
15.

Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens.

Chen TY, Jain MK.

AIDS Patient Care STDS. 2015 Jun;29(6):329-37. doi: 10.1089/apc.2014.0247.

PMID:
26020726
16.

Hepatitis C virus-HIV-coinfected patients and liver transplantation.

Kardashian AA, Price JC.

Curr Opin Organ Transplant. 2015 Jun;20(3):276-85. doi: 10.1097/MOT.0000000000000199.

PMID:
25944240
17.

Synthesis, crystal structures and docking studies of 2,7-diphenyl-1,4-diazepan-5-one derivatives.

Velusamy M, Sreenivasan S, Kandasamy R, Subbu P, Paramasivam S, Mondikalipudur Nanjappagounder P.

Chem Cent J. 2015 Apr 8;9:17. doi: 10.1186/s13065-015-0094-3. eCollection 2015.

18.

Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.

Meemken L, Hanhoff N, Tseng A, Christensen S, Gillessen A.

Ann Pharmacother. 2015 Jul;49(7):796-807. doi: 10.1177/1060028015581848. Epub 2015 Apr 22. Review.

PMID:
25902733
19.

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications.

Kaur K, Gandhi MA, Slish J.

Infect Dis Ther. 2015 Jun;4(2):159-72. doi: 10.1007/s40121-015-0061-2. Epub 2015 Apr 21.

20.

A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation.

Cirioni O, Weimer LE, Fragola V, Giacometti A, Ancarani F, Maracci M, Gabrielli E, Marchionni E, Pirillo MF, Vella S.

West Indian Med J. 2014 Sep 3;63(7). doi: 10.7727/wimj.2013.264. [Epub ahead of print]

PMID:
25867565
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk